M. ADULT RAPID SEQUENCE INTUBATION PROTOCOL PACKAGE

1. Rapid Sequence Intubation (RSI) Pilot Program

a) Indications
   (1) Inability to tolerate laryngoscopy, and:
       (a) GCS less than or equal to 8 with respiratory rate less than or equal to 8 or greater than or equal to 35 or
       (b) GCS less than or equal to 8 with oxygen saturation less than or equal to 90% on non-rebreather face mask
   (2) On-line medical direction for RSI may be requested in the following situations:
       (a) GCS less than or equal to 8 with clenched jaw, inability to adequately suction airway, and without above respiratory parameters
       (b) Respiratory extremis with contraindications to nasotracheal intubation (respiratory rate greater than or equal to 35 with air hunger, use of accessory muscles, and oxygen saturation less than or equal to 90% on non-rebreather face mask)

b) Contraindications
   (1) Conditions that may cause hyperkalemia:
       (a) Burns greater than 24 hours old
       (b) Spinal cord injury greater than 24 hours old
       (c) Known neuromuscular disease (Guillain-Barré Syndrome, myasthenia gravis, amyotrophic lateral sclerosis, muscular dystrophy)
       (d) Chronic renal failure on hemodialysis/Presence of hemodialysis access
   (2) Patients who have not yet reached their 15th birthday (NEW '15)
   (3) History of malignant hyperthermia

c) Preparation
   (1) Pre-oxygenate with 90–100% oxygen.
   (2) Monitor oxygen saturation with pulse oximetry and EKG.
   (3) Ensure functioning IV and fluid therapy as per protocol.
   (4) Evaluate for difficult airway.
   (5) Perform focused RSI neurologic exam.
   (6) Prepare equipment
       (a) Intubation kit
       (b) Bag-Valve-Mask (BVM)
       (c) Suction
       (d) RSI kit
           (i) Prepare medications
           (ii) Alternative airway device, Cricothyroidotomy equipment
       (e) Capnograph
d) RSI Procedure

(1) Sedation
Adequate sedation must be provided to prevent awareness during paralysis from neuromuscular blockade.

Etomidate, if available, will be the preferred agent for patients who are aware of their surroundings and do not have hypotension or possible hypovolemia.

Dose: Administer 0.3 mg/kg IVP over 30–60 seconds. May repeat 0.15 mg/kg IVP in 2–3 minutes if inadequate sedation.

OR

Ketamine may be used if etomidate is unavailable, and may be preferred for patients who have hypotension or possible hypovolemia.

Dose: Administer 2 mg/kg IVP over 60 seconds.

OR

Midazolam should be considered for patients with isolated head injury and elevated blood pressure, especially with possible seizure activity. Midazolam should not be used for patients with hypotension, and should be avoided with possible hypovolemia.

Dose: Administer 0.05 mg/kg IVP over 1–2 minutes.

Maximum single dose is 5 mg.

Only one sedative agent should be administered prior to succinylcholine unless otherwise directed by medical consultation.

(2) For patients with head injury or suspected increased intracranial pressure, administer lidocaine 1 mg/kg (40–100 mg) IVP over 1–2 minutes.

(3) In-line cervical spine stabilization by second caregiver (in trauma setting)

(4) Apply cricoid pressure (by third caregiver).

(5) Succinylcholine: Administer 1.5 mg/kg rapid IVP. Maximum single dose is 200 mg.

(6) Intubate trachea and verify ET placement.

(7) If inadequate relaxation after 2–3 minutes, administer atropine 1 mg to avoid bradycardic response and repeat succinylcholine 1 mg/kg IVP. Maximum single dose is 200 mg.

e) Successful Endotracheal Tube Placement

(1) Release cricoid pressure and secure ET.

(2) Ventilate to end-tidal carbon dioxide of 30–32 mmHg.

(3) If significant resistance to ventilation occurs as succinylcholine wears off (4–5 minutes), refer to Ventilatory Difficulty Secondary to Bucking Protocol.

f) Unsuccessful Endotracheal Tube Placement

(1) Maintain cricoid pressure and resume BVM ventilation for 30 seconds.

(2) If unable to ventilate, see “Unable to Ventilate” below.

(3) Re-attempt oral ET intubation.

(4) If unsuccessful, resume BVM ventilation for 30 seconds.

(5) Insert an approved alternative airway device (refer to Alternative Airway Device protocol).
(6) Attach capnograph and ventilate to desired end-tidal carbon dioxide level.

(7) If significant resistance to ventilation occurs as succinylcholine wears off (4–5 minutes), or if patient exhibits difficulty in tolerating an approved alternative airway device as succinylcholine wears off, refer to Ventilatory Difficulty Secondary to Bucking Protocol.

g) If Unable to Ventilate
   Insert an approved alternative airway device (refer to Alternative Airway Device protocol).

h) If still unable to ventilate using an approved alternative airway device, remove and perform cricothyroidotomy (refer to cricothyroidotomy Protocol).

2. Ventilatory Difficulty Secondary to Bucking or Combativeness in Intubated Patients

a) Indication
   Patients successfully intubated with an endotracheal tube, an approved alternative airway device, or cricothyroidotomy, for whom the ability to provide manual or mechanical ventilation is impaired secondary to bucking or combativeness

b) Contraindication
   Unsecured airway

c) Procedure
   (1) Etomidate, if available, will be the preferred agent for patients who are aware of their surroundings and do not have hypotension or possible hypovolemia.
      Dose: Administer 0.3 mg/kg IVP over 30–60 seconds.
      May repeat 0.15 mg/kg IVP every 15 minutes to a total of three doses.
      OR
   Ketamine may be used if etomidate is unavailable, and may be preferred for patients who have hypotension or possible hypovolemia, or if ventilatory difficulty is thought to be the result of pain response.
      Dose: Administer 2 mg/kg IVP over 60 seconds. May repeat 1 mg/kg for IVP every 10–15 minutes to a total of three doses as necessary. Additional doses require medical consultation.
      OR
   Midazolam should be considered for patients with isolated head injury and elevated blood pressure, especially with possible seizure activity. Midazolam should not be used for patients with hypotension, and should be avoided with possible hypovolemia.
      Dose: Administer 0.05 mg/kg IVP over 1–2 minutes, titrated to abate bucking and relax ventilation while maintaining systolic BP greater than 90 mmHg. Maximum single dose is 5 mg.
(2) If ventilatory difficulty is thought to be the result of pain response, **Ketamine**: Dose 2 mg/kg IVP over 60 seconds. May repeat 1 mg/kg IVP every 10–15 minutes as necessary to a total of three doses as necessary. Additional doses require medical consultation.

**OR**

Opioid may be used per Pain Management protocol in addition to, or instead of, midazolam, ketamine, or etomidate. Titrate to abate bucking and relax ventilation while maintaining systolic BP greater than 90 mmHg.

(3) If significant resistance to ventilation continues, the Paramedic may administer:

(a) Vecuronium 0.05 mg/kg IVP. Maximum single dose is 10 mg.

PRE-SEDATION MUST BE PROVIDED WHEN VECURONIUM IS ADMINISTERED TO A PATIENT WHO IS EITHER RESPONSIVE TO STIMULUS, OR WHO MAY BECOME RESPONSIVE TO STIMULUS DURING NEUROMUSCULAR BLOCKADE. USE OF VECURONIUM REQUIRES FUNCTIONING END-TIDAL CO₂ MONITORING. VECURONIUM MAY ONLY BE USED IF CONTINUOUS, BREATH TO BREATH ETCO₂ MONITORING CAN BE PROVIDED.

(b) Dose may be repeated in 4–6 minutes if necessary.

(c) **Maintenance of Amnesia**

   Follow above dosing of either etomidate or ketamine with required repeat dosing every 10–15 minutes.

(4) Continue to monitor oxygen saturation and ventilate to desired end-tidal carbon dioxide.

(5) Obtain on-line medical direction if further problems present.
3. Protocol for Cricothyroidotomy (Surgical and Needle)

a) Indications
   (1) Inability to ventilate despite having tried BVM with oropharyngeal/nasopharyngeal airway, ET placement, and an alternative airway device (if not contraindicated)
   (2) Inability to place ET in the setting of life-threatening upper airway hemorrhage
   (3) Completely obstructing upper airway foreign body that cannot be removed via BLS maneuvers or Magill forceps with direct visualization

b) Preparation
   (1) Prepare suction and cricothyroidotomy kit.
   (2) Begin at sternal notch and locate cricoid cartilage.
   (3) Palpate cricothyroid membrane anteriorly between cricoid cartilage and thyroid cartilage.
   (4) Prepare skin with betadine or alcohol swabs.

c) Surgical Cricothyroidotomy
   (1) Stabilize thyroid cartilage and make vertical incision (1–1½ inches) over cricothyroid membrane. Alternatively, a needle puncture dilator device may be utilized.
   (2) Palpate cricothyroid membrane with gloved finger and carefully make transverse incision through membrane. Insert scalpel handle and rotate 90 degrees.
   (3) Insert a 6.0 mm cuffed ET tube, using the natural curve of tube.
   (4) Insert ET tube to just beyond cuff.
   (5) Inflate cuff and ventilate patient.
   (6) Monitor oxygen saturation and end-tidal carbon dioxide level.
   (7) Secure ET tube. (Do not cut or trim ET tube.)
   (8) If significant resistance to ventilation develops, or if patient develops difficulty in tolerating successful cricothyroidotomy, refer to Ventilatory Difficulty Secondary to Bucking or Combativeness Protocol.
Protocol for Cricothyroidotomy (Continued)

d) Needle Cricothyroidotomy

ONLY NEEDLE CRICOTHYROIDOTOMY SHOULD BE PERFORMED FOR PATIENTS LESS THAN THE AGE OF 8 WHO REQUIRE CRICOTHYROIDOTOMY.

(1) Insert 12- or 14-gauge over-the-needle catheter through the cricothyroid membrane at a 45-degree angle toward the feet. Aspiration of air with a syringe indicates tracheal entry.
(2) Hold needle in place and advance catheter, then remove needle.
(3) Attach catheter hub to intermittent jet oxygen insufflator valve.
(4) Manually secure catheter at hub at all times to prevent kinking or displacement.
(5) Monitor oxygen saturation.
(6) If significant resistance to ventilation develops, or if patient develops difficulty in tolerating cricothyroidotomy, refer to Ventilatory Difficulty Secondary to Bucking or Combativeness Protocol.
4. RSI Quality Assurance Process

a) Individual Paramedic Approval for RSI Pilot Participation
   (1) Successful completion of small group training includes all five of the following:
      (a) Classroom lecture
      (b) Mannequin instruction
      (c) Cadaver lab, including cricothyroidotomy
      (d) Anesthesia computerized mannequin simulator
      (e) Must demonstrate proficiency through skills testing and written test
   (2) Successful completion of individualized Operating Room Training
      (a) Individual Operating Room training with Attending Anesthesiologist, and
      (b) Must demonstrate proficiency to Attending Anesthesiologist’s satisfaction

b) Ongoing Demonstration of Proficiency
   A verification of all RSI skills and review of RSI principles of safety will be performed on a quarterly basis. In two of the quarters, this will be accomplished via direct observation in the operating room. In a third quarter, the medical director will perform this during a full Paramedic skills evaluation. A fourth quarter verification will be accomplished via an anesthesia mannequin simulator, an RSI skills module, or a documentation and review of a field utilization.

c) Review of Each Call
   (1) Mechanism for follow-up of each call will be in accordance with the Quality Review Procedure for Pilot Programs (formerly “Class B” Additional Procedure Algorithm) of the Maryland Medical Protocols, with the following additions:
      (a) Immediate notification of your jurisdictional RSI supervisor for all RSI attempts
      (b) Medical Director evaluation of all RSI attempts within 12 hours

d) Maintenance of detailed RSI database
N. PEDIATRIC RAPID SEQUENCE INTUBATION PROTOCOL PACKAGE
(For children who have not yet reached their 15th birthday (NEW ’15))

1. Rapid Sequence Intubation (RSI) Pilot Program

   a) Indications

      (1) Inability to tolerate laryngoscopy and have the following:

          (a) GCS less than or equal to 8, indicated by a patient that will not:
              open eyes, cry, say words, or show purposeful movement in
              response to painful stimulus.

          AND

          (b) Respiratory insufficiency, demonstrated by oxygen saturation less
              than or equal to 90% on non-rebreather face mask, respiratory
              rate less than or equal to 8, or respiratory rate greater than or
              equal to 45 (age less than 1 yr), greater than or equal to 40 (age
              1–5 yrs), greater than or equal to 35 (age 6–9 yrs) with signs of air
              hunger and accessory muscle use.

          PATIENTS WITH AN IDENTIFIED DIFFICULT AIRWAY WHO CAN BE BAGGED TO AN
          OXYGEN SATURATION GREATER THAN 90% REQUIRE ON-LINE MEDICAL DIRECTION
          FOR RSI, PREFERABLY FROM A PEDIATRIC BASE STATION.

          (2) On-line medical direction for RSI may be requested (preferably
              from a pediatric Base Station), in the following situations:

              (a) GCS less than or equal to 8 with clenched jaw, inability to
                  adequately suction airway, and without above respiratory
                  parameters

              (b) Respiratory extremis with contraindications to nasotracheal
                  intubation (respiratory rate greater than or equal to 35 with air
                  hunger, use of accessory muscles, and oxygen saturation less
                  than or equal to 90% on non-rebreather face mask)

              (c) Identified difficult airway patient with a GCS less than or equal
                  to 8 and signs of respiratory insufficiency who cannot tolerate
                  laryngoscopy but is able to be bagged to an oxygen saturation
                  greater than 90%

   b) Contraindications

      (1) Conditions that may cause hyperkalemia:

          (a) Burns greater than 24 hours old

          (b) Spinal cord injury greater than 24 hours old

          (c) Known neuromuscular disease (Guillain-Barré Syndrome,
              myasthenia gravis, amyotrophic lateral sclerosis,
              muscular dystrophy)

          (d) Chronic renal failure on hemodialysis/presence of hemodialysis
              access

      (2) History of malignant hyperthermia
c) Preparation
   (1) Pre-oxygenate with 90–100% oxygen.
   (2) Monitor oxygen saturation with pulse oximetry and EKG.
   (3) Ensure functioning IV and fluid therapy as per protocol.
   (4) Evaluate for difficult airway.
   (5) Perform focused RSI neurologic exam.
   (6) Prepare equipment
      (a) Intubation kit: Recommended to carry both cuffed and uncuffed ET tubes for patients less than 8 years of age or 25 kg.
      (b) Bag-Valve-Mask (BVM) with manometer. (Manometer may be part of the BVM or separate.)
      (c) Suction
      (d) RSI kit
         (i) Prepare medications
         (ii) Alternative airway device, Cricothyroidotomy equipment
      (e) Capnograph

d) RSI Procedure
   (1) Adequate sedation must be provided to prevent awareness during paralysis from neuromuscular blockade.

   **Etomidate**, if available, will be the preferred agent for patients who are aware of their surroundings and do not have hypotension or possible hypovolemia.
   Dose: Administer 0.3 mg/kg IVP over 30–60 seconds. May repeat 0.15 mg/kg IVP in 2–3 minutes if inadequate sedation.

   **Ketamine** may be used if etomidate is unavailable, and may be preferred for patients who have hypotension or possible hypovolemia.
   Dose: Administer 2 mg/kg IVP over 60 seconds.

   **Midazolam** should be considered for patients with isolated head injury and elevated blood pressure, especially with possible seizure activity. Midazolam should not be used for patients with hypotension, and should be avoided with possible hypovolemia.
   Dose: Administer 0.05 mg/kg IVP over 1–2 minutes. Maximum single dose is 5 mg.
      (a) Hold for BP less than 60 in neonates (patients less than 28 days old), less than 70 in infants (patients less than 1 year of age), less than [70 + (2 x years) = systolic BP] for patients greater than 1 year of age.

   (2) For patients with head injury or suspected increased intracranial pressure, administer lidocaine 1 mg/kg IVP over 1–2 minutes.

   (3) If patient is less than 8 years of age (or if age unknown and using ET tube smaller than 6.0), pretreat patient with atropine 0.02 mg/kg IVP (minimum dose of 0.1 mg).

   (4) In-line cervical spine stabilization by second caregiver (in trauma setting)
(5) Apply cricoid pressure (by third caregiver).
(6) Succinylcholine: Administer 1.5 mg/kg rapid IVP.
(7) Intubate trachea and verify ET placement.
(8) If inadequate relaxation after 2–3 minutes, repeat succinylcholine 0.5 mg/kg IVP.

**e) Successful Endotracheal Tube Placement**
(1) Release cricoid pressure and secure ET.
(2) Ventilate to end-tidal carbon dioxide of 30–32 mmHg.
(3) If significant resistance to ventilation occurs as succinylcholine wears off (4–5 minutes), refer to Ventilatory Difficulty Secondary to Bucking Protocol.

**f) Unsuccessful Endotracheal Tube Placement**
(1) Maintain cricoid pressure and resume BVM ventilation for 30 seconds.
(2) If unable to ventilate, see “If Unable to Ventilate” below.
(3) Re-attempt oral ET intubation.
(4) If unsuccessful, resume BVM ventilation.

**g) If Unable to Ventilate**
If unable to ventilate, verify appropriate oropharyngeal airway placement and reposition BVM for optimal mask seal. If still unable to ventilate, refer to Needle Cricothyroidotomy protocol.

2. **Ventilatory Difficulty Secondary to Bucking or Combativeness in Intubated Patients**

**a) Indication**
Patients successfully intubated with an endotracheal tube, or needle cricothyroidotomy, for whom the ability to provide manual or mechanical ventilation is impaired secondary to bucking or combativeness

**b) Contraindication**
Unsecured airway

**c) Procedure**
(1) **Etomidate**, if available, will be the preferred agent for patients who are aware of their surroundings and do not have hypotension or possible hypovolemia.
   Dose: Administer 0.3 mg/kg IVP over 30–60 seconds. May repeat 0.15 mg/kg IVP every 15 minutes to a total of three doses.

   **OR**

   **Ketamine** may be used if etomidate is unavailable, and may be preferred for patients who have hypotension or possible hypovolemia, or if ventilatory difficulty is thought to be the result of pain response.
   Dose: Ketamine: 2 mg/kg IVP over 60 seconds. May repeat 1 mg/kg for IVP every 10–15 minutes to a total of three doses as necessary. Additional doses require medical consultation.

   **OR**
Midazolam should be considered for patients with isolated head injury and elevated blood pressure, especially with possible seizure activity. Midazolam should not be used for patients with hypotension, and should be avoided with possible hypovolemia.

Dose: Administer 0.05 mg/kg IVP over 1–2 minutes, titrated to abate bucking and relax ventilation while maintaining systolic BP: greater than 60 in neonates, 70 in infants, [70 + (2 x years) = systolic BP] for patients greater than 1 year of age. Maximum single dose is 5 mg.

(2) If ventilatory difficulty is thought to be the result of pain response, **Ketamine**: Dose: 2 mg/kg IVP over 60 seconds. May repeat 1 mg/kg IVP every 10–15 minutes as necessary to a total of three doses as necessary. Additional doses require medical consultation. **OR**

Opioid may be used per Pain Management protocol in addition to, or instead of, midazolam, ketamine, or etomidate. Titrate to abate bucking and relax ventilation while maintaining systolic BP greater than 60 in neonates, 70 in infants, [70 + (2 x years) = systolic BP] for patients greater than 1 year of age.

(3) If significant resistance to ventilation continues, the Paramedic may administer:

(a) Vecuronium 0.05 mg/kg IVP (may not be used for patients with needle cricothyroidotony because of inability to monitor breath to breath ETCO₂). Maximum single dose is 10 mg.

**PRE-SEDATION MUST BE PROVIDED WHEN VECCURONIUM IS ADMINISTERED TO A PATIENT WHO IS EITHER RESPONSIVE TO STIMULUS OR MAY BECOME RESPONSIVE TO STIMULUS DURING NEUROMUSCULAR BLOCKADE. VECCURONIUM MAY ONLY BE USED IF CONTINUOUS, BREATH TO BREATH ETCO₂ MONITORING CAN BE PROVIDED.**

(b) Dose may be repeated in 4–6 minutes if necessary.

(c) **Maintenance of Amnesia**

   Follow above dosing of either etomidate or ketamine with required repeat dosing every 10–15 minutes.

(4) Continue to monitor oxygen saturation and ventilate to desired end-tidal carbon dioxide.

(5) Obtain on-line medical direction (preferably from a pediatric Base Station), if further problems present.
3. Protocol for Cricothyroidotomy

Surgical (for 8 years old or greater) and Needle

a) Indications
(1) Inability to ventilate despite having tried BVM with oropharyngeal/nasopharyngeal airway, ET placement, and alternative airway device (if not contraindicated)
(2) Inability to place ET in the setting of life-threatening upper airway hemorrhage
(3) Completely obstructing upper airway foreign body that cannot be removed via BLS maneuvers or Magill forceps with direct visualization

b) Preparation
(1) Prepare suction and cricothyroidotomy kit.
(2) Begin at sternal notch and locate cricoid cartilage.
(3) Palpate cricothyroid membrane anteriorly between cricoid cartilage and thyroid cartilage.
(4) Prepare skin with betadine or alcohol swabs.

c) Surgical Cricothyroidotomy for 8 years old or greater
(1) Stabilize thyroid cartilage and make vertical incision (1–1 1/2 inches) over cricothyroid membrane. Alternatively, a needle puncture dilator device may be utilized.
(2) Palpate cricothyroid membrane with gloved finger and carefully make transverse incision through membrane. Insert scalpel handle and rotate 90 degrees.
(3) Insert a 5 to 6.0 mm cuffed ET tube, using the natural curve of tube.
(4) Insert ET tube to just beyond cuff.
(5) Inflate cuff and ventilate patient.
(6) Monitor oxygen saturation and end-tidal carbon dioxide level.
(7) Secure ET tube. (Do not cut or trim ET tube.)
(8) If significant resistance to ventilation develops, or if patient develops difficulty in tolerating successful cricothyroidotomy, refer to Ventilatory Difficulty Secondary to Bucking or Combativeness Protocol.

ONLY NEEDLE CRICOPTHYROIDOTOMY SHOULD BE PERFORMED FOR PATIENTS LESS THAN AGE 8 WHO MAY REQUIRE CRICOPTHYROIDOTOMY.

d) Needle Cricothyroidotomy
(1) Insert 12- or 14-gauge over-the-needle catheter through the cricothyroid membrane at a 45-degree angle toward the feet. Aspiration of air with a syringe indicates tracheal entry.
(2) Hold needle in place and advance catheter, then remove needle.
(3) Attach catheter hub to intermittent jet oxygen insufflator valve.
(4) Manually secure catheter at hub at all times to prevent kinking or displacement.
(5) Monitor oxygen saturation.
(6) If significant resistance to ventilation develops, or if patient develops difficulty in tolerating cricothyroidotomy, refer to Ventilatory Difficulty Secondary to Bucking or Combativeness Protocol.

4. Pediatric RSI Quality Assurance Process

a) Individual Paramedic Approval for Pediatric RSI Pilot Participation
   (1) Successful completion of small group training includes all of the following:
      (a) Classroom lecture
      (b) Mannequin instruction
      (c) Must demonstrate proficiency through skills testing and written test
   (2) Successful completion of individualized Operating Room Training
      (a) Individual Operating Room Training with Pediatric/Critical Care/Anesthesiology Attending approved by the Associate State EMS Medical Director for Pediatrics
      (b) Must demonstrate proficiency to Attending Pediatric/Critical Care/Anesthesiologist’s satisfaction

b) Ongoing Demonstration of Proficiency
   A verification of all pediatric and adult RSI skills and review of pediatric and adult RSI principles of safety will be performed on a quarterly basis.

c) Review of Each Call
   (1) Mechanism for follow-up of each call will be in accordance with the Quality Review Procedure for Pilot Programs (formerly “Class B” Additional Procedure Algorithm) of the Maryland Medical Protocols, with the following additions:
      (a) Immediate notification to jurisdictional RSI supervisor for all RSI attempts
      (b) Medical Director evaluation of all RSI attempts within 12 hours

d) Maintenance of detailed RSI database
N1. RAPID SEQUENCE INTUBATION PHARMACOLOGY

1. Etomidate (Amidate)
   a) Pharmacology
      Hypnotic
   b) Pharmacokinetics
      A short-acting nonbarbiturate hypnotic agent without analgesic properties
   c) Indications
      Pre-sedation of responsive patients prior to administration of neuromuscular blocking agents
   d) Contraindications
      Known hypersensitivity to etomidate
   e) Adverse Effects
      (1) Respiratory depression or apnea
      (2) Hypotension (infrequent)
      (3) Involuntary myoclonus
      (4) Adrenal suppression (possible with repeated dosing)
   f) Precautions
      (1) The effects of etomidate can be accentuated by CNS depressants such as opioids and alcohol.
      (2) Myoclonic movements are common and should not be confused for fasciculations due to a depolarizing neuromuscular blocking agent or seizure activity.
   g) Dosage
      (1) Adult:
         Administer 0.3 mg/kg IVP over 30–60 seconds.
         If the provider suspects hypovolemia, the initial dose will be 0.15 mg/kg IVP over 30–60 seconds. May repeat 10 mg for adult IVP after succinylcholine effects resolve and patient is bucking or combative. May repeat 10 mg for adult IVP every 15 minutes to a total of three doses. Additional doses require medical consultation.
      (2) Pediatric:
         Administer 0.3 mg/kg IVP over 30–60 seconds.
         If the provider suspects hypovolemia, the initial dose will be 0.15 mg/kg IVP over 30–60 seconds. May repeat 0.15 mg/kg IVP after succinylcholine effects resolve and patient is bucking or combative. May repeat 0.15 mg/kg IVP every 15 minutes to a total of three doses. Additional doses require medical consultation.
2. KETAMINE (KENTANEST, KETASET, KETALAR)

a) Pharmacology
   Hypnotic Analgesic

b) Pharmacokinetics
   A rapid-acting nonbarbiturate hypnotic analgesic agent characterized by normal pharyngeal-laryngeal reflexes, normal or enhanced skeletal muscle tone, and possible cardiovascular and respiratory stimulation.

c) Indications
   (1) Pre-sedation of responsive patients prior to administration of neuromuscular blocking agents
   (2) Sedation of intubated patients with ventilatory difficulty secondary to bucking or combativeness

d) Contraindications
   Known hypersensitivity to ketamine

e) Adverse Effects
   (1) Although respiration is frequently stimulated, respiratory depression may occur with rapid IV administration. Laryngospasm has been known to occur.
   (2) Although hypotension may occur, blood pressure and heart rate are frequently stimulated.
   (3) Involuntary myoclonus that may mimic seizure activity
   (4) Possible enhanced secretions
   (5) Possible unpleasant dreams and delirium upon emergence from sedation

f) Precautions
   (1) The likelihood of respiratory depression and undesired pressor effects is increased by too rapid IV administration.
   (2) Myoclonic movements are possible and should not be confused for fasciculations due to a depolarizing neuromuscular blocking agent, seizure activity, or emergence from sedation.

g) Dosage
   (1) Adult:
       Administer 2 mg/kg IVP over 60 seconds.
       May repeat 2 mg/kg IVP after succinylcholine effects resolve if patient is bucking or combative.
       May repeat 1 mg/kg for IVP every 10–15 minutes to a total of three doses as necessary. Additional doses require medical consultation.
   (2) Pediatric:
       Administer 2 mg/kg IVP over 60 seconds.
       May repeat 2 mg/kg IVP after succinylcholine effects resolve if patient is bucking or combative.
       May repeat 1 mg/kg for IVP every 10–15 minutes to a total of three doses as necessary. Additional doses require medical consultation.
3. MIDAZOLAM (VERSED)

a) Pharmacology
   (1) Sedative
   (2) Hypnotic

b) Pharmacokinetics
   A short-acting benzodiazepine with strong hypnotic and amnestic properties

c) Indications
   (1) Pre-sedation of responsive patients prior to administration of neuro-muscular blocking agents
   (2) Sedation of intubated patients with ventilatory difficulty secondary to bucking or combativeness

d) Contraindications
   (1) Hypotension
   (2) Acute narrow-angle glaucoma
   (3) Known hypersensitivity to midazolam

e) Adverse Effects
   (1) Respiratory depression or apnea
   (2) Hypotension
   (3) Amnesia

f) Precautions
   The effects of midazolam can be accentuated by CNS depressants such as opioids and alcohol

g) Dosage
   (1) Adult:
      Administer 0.05 mg/kg, slow IVP over 1–2 minutes, while maintaining systolic BP greater than 90 mmHg. Maximum single dose is 5 mg.
   (2) Pediatric:
      Administer 0.05 mg/kg slow IVP over 1–2 minutes, while maintaining systolic BP greater than 60 in neonates, 70 in infants,
      \[70 + (2 \times \text{years}) = \text{systolic BP}\] for patients greater than 1 year of age.
      Maximum single dose is 5 mg.

   **ALERT** ADMINISTER UP TO 0.05 MG/KG IV WHEN TREATING ENDOTRACHEAL TUBE BUCKING, STOPPING ONCE BUCKING HAS RESOLVED AND VENTILATION IS RELAXED.
4. SUCCINYLCHOLINE (ANECTINE)

   a) Pharmacology
      Neuromuscular blocking agent (depolarizing)

   b) Pharmacokinetics
      Paralyzes skeletal muscles, including respiratory muscles, and
      removes gag reflex

   c) Indications
      To achieve paralysis to facilitate endotracheal intubation in patients
      as per Rapid Sequence Intubation Protocol

   d) Contraindications
      (1) Conditions that may cause hyperkalemia:
          (a) Burns greater than 24 hours old
          (b) Spinal cord injury greater than 24 hours old
          (c) Known neuromuscular disease (Guillain-Barré Syndrome,
              myasthenia gravis, amyotrophic lateral sclerosis, muscular
dystrophy)
          (d) Chronic renal failure on hemodialysis or presence of hemodialysis
              access
      (2) History of malignant hyperthermia
      (3) Patients with known hypersensitivity to the drug

   e) Adverse Effects
      (1) Bradycardia
      (2) Prolonged paralysis

   f) Precautions
      Paralysis occurs in 1–2 minutes and generally lasts 4–6 minutes.

   g) Dosage/Route
      (1) Adult:
          Administer 1.5 mg/kg rapid IVP to a maximum single dose of 200 mg.
          If relaxation is inadequate after 2–3 minutes, a repeat dose of
          1 mg/kg rapid IVP may be given to a maximum single dose of 200 mg.
      (2) Pediatric:
          Administer 1 mg/kg rapid IVP to a maximum dose of 200 mg.
          If relaxation is inadequate after 2–3 minutes, a repeat dose of
          1 mg/kg rapid IVP may be given to a maximum dose of 200 mg.
5. **VECURONIUM (NORCURON)**

   a) **Pharmacology**
      Neuromuscular blocking agent (non-depolarizing)

   b) **Pharmacokinetics**
      (1) Skeletal muscle relaxant
      (2) Paralyzes skeletal muscles, including respiratory muscles

   c) **Indications**
      For treatment of ventilatory difficulty secondary to bucking or combativeness in intubated patients

   d) **Contraindications**
      (1) Non-intubated patients
      (2) Patients with known hypersensitivity to the drug

   e) **Adverse Effects**
      (1) Bradycardia
      (2) Prolonged paralysis

   f) **Precautions**
      (1) Pre-sedation must be provided when vecuronium is administered to a patient who is either responsive to stimulus or who may become responsive to stimulus during neuromuscular blockade.
      (2) Paralysis occurs within 2–4 minutes and generally lasts 25–40 minutes.

   g) **Dosage/Route**
      (1) Adult:
         Administer 0.05 mg/kg IVP. Maximum single dose is 10 mg.
      (2) Pediatric:
         Administer 0.05 mg/kg IVP.
      (3) If bucking or combativeness persists 4–6 minutes after initial vecuronium administration, a second dose of 0.05 mg/kg IV may be administered for an adult or pediatric patient. Maximum single dose is 10 mg.
THIS PAGE IS INTENTIONALLY BLANK
THIS PAGE IS INTENTIONALLY BLANK
N2. EMT Acquisition of 12-Lead Electrocardiography

1. PURPOSE

Coronary heart disease is the single largest cause of death in U.S. men and women. Early identification and treatment of patients with acute myocardial infarction (AMI) has proven to reduce myocardial damage and decrease morbidity and mortality. The goal of this program is to allow an EMT to acquire and transmit a 12-lead (15-lead if trained to perform) electrocardiography (EKG) to the receiving facility and possibly reduce the door to reperfusion time for the AMI patient.

2. PRESENTATION

Chest discomfort that may radiate to the arm, shoulders, jaw, or back. Generally described as a crushing pain or toothache. May be accompanied by shortness of breath, sweating, nausea, or vomiting.

OR

a) Chest discomfort. Some heart attacks involve discomfort in the center of the chest that lasts for more than a few minutes or that goes away and comes back. This discomfort can feel like uncomfortable pressure, squeezing, or fullness.

b) Discomfort in other areas of the upper body. Symptoms can include discomfort in one or both arms or in the back, neck, jaw, or stomach.

c) Shortness of breath. This symptom often accompanies chest discomfort. However, it can also occur prior to the chest discomfort.

d) Other signs. These may include breaking out in a cold sweat, nausea, light-headedness, or a sense of impending doom.

e) Post cardiac arrest with ROSC.

f) Medical history and contributing factors.

   (1) A previous heart attack or procedure to open up coronary arteries
   (2) Family history of heart disease
   (3) Diabetes mellitus
   (4) High blood pressure
   (5) High blood cholesterol
   (6) Overweight
   (7) Physical inactivity
   (8) Cigarette smoking
3. INDICATIONS

Any patient complaining of chest discomfort or exhibiting signs, symptoms, or medical history as outlined in Section 2 (Presentation).

4. CONTRAINDICATIONS

Acquisition of a 12-lead EKG should not take precedence over required life-saving measures (e.g., CPR, assisting respirations, clearing or maintaining a patient’s airway, checking blood glucose, extrication, or removing a patient from a dangerous scene).

5. PROCEDURE

a) Initiate General Patient Care.

b) Initiate Cardiac Emergencies: Chest Pain Protocol.

c) Position patient (1) (2).

d) Place chest and limb leads (3) (4).

e) Turn on monitor.

f) Set patient age and a patient identifier.

g) Acquire 12-lead (5).

h) Consult with receiving facility.

i) Transmit 12-lead (6).

j) Continue patient care.

(1) Unrestricted access to the skin in the chest area, arms, and lower legs is required to allow for correct placement of electrodes. Do your best to protect the patient’s privacy. Once the electrodes are positioned and connecting leads are appropriately attached, the patient should be covered with a sheet to preserve his/her dignity during the procedure.

(2) If unable to place patient in the recumbent position, include this information in your hospital consult and note it in the written narrative of your patient care report.
(3) Remove electrodes from a sealed package immediately before use. Using previously unpacked electrodes or electrodes with expired date codes may impair EKG signal quality.

(4) When placing electrodes on female patients, always place the leads V3-V6 under the breast rather than on the breast.

(5) Acquisition of a 12-lead EKG should take no more than 5 minutes.

(6) Transmission of the 12-lead EKG to the receiving facility should be done en route to the receiving facility. There is no need to delay transport to transmit a 12-lead EKG.

6. INDIVIDUAL EMT APPROVAL FOR PARTICIPATION

   a) The EMT 12-Lead EKG Program is open to all Maryland EMTs that have been providing direct patient care for a minimum of one year.

   b) Providers must be members of an ALS company that currently owns a local system compatible 12-lead device.

7. ONGOING DEMONSTRATION OF PROFICIENCY

   After the initial training program is completed, the EMT will participate in an annual refresher training program.

8. REVIEW OF EACH CALL

   a) The provider will submit copies of each 12-lead EKG and patient care report to his/her jurisdictional Quality Review Committee.

   b) The Quality Review Committee will review all 12-lead transmissions on a quarterly basis and submit a report to Jurisdictional and Regional Medical Directors.
N3. PELVIC STABILIZATION BINDER DEVICE
All levels of EMS providers, if appropriately trained in the device

1. INDICATIONS
All of the following blunt trauma patients with physical findings indicative of pelvic fracture should have a Pelvic Stabilization Binder Device applied.
   a) Evidence of pelvic instability on examination of the pelvis
   b) Patients complaining of pelvic pain on examination of the pelvis
   c) Pain on iliac compression
   d) Pain on compression of the pubic symphysis
   e) Blood at the urethral meatus
   f) Vaginal bleeding
   g) Perineal or scrotal hematoma
   h) All blunt trauma patients with an unreliable physical exam and significant mechanism of injury may be considered for application of a Pelvic Stabilization Binder Device.

PREGNANCY IS NOT A CONTRAINDICATION TO THE APPLICATION OF THE PELVIC STABILIZATION BINDER DEVICE WHEN INDICATED.

2. CONTRAINDICATIONS
Children who have not reached their 15th birthday

3. PROCEDURE
   a) Assess for pelvic instability.
      In order to not increase bleeding, only one exam should be performed to evaluate for pelvic fracture. Multiple exams will disrupt clot formation.
   b) Identify the greater trochanter of each femur.
      The greater trochanter is the bony prominence of the lateral upper thigh.
   c) The patient should be placed in a supine position prior to application of the pelvic stabilization binder device.
   d) Place pelvic binder around the patient, centered at the level of the greater trochanter.
   e) It may be advisable to place the binder on the backboard prior to placing the patient onto the backboard so that it is already prepared for placement.
   f) Ensure patient has been undressed and provides adequate exposure.
   g) Tighten the binder as directed by the manufacturer’s instructions for the specific stabilization binder.
   h) Once pelvic stabilization binder device is applied, do not remove until directed to do so by a physician.
4. PRECAUTIONS
   
a) Incorrectly placing the pelvic stabilization binder device at the level of the iliac wing could cause harm by widening the pelvic fracture. Assess after application of the pelvic stabilization binder device.

b) Continue with patient care.

c) EMS providers should also assess distal pulses before and after the application of the pelvic stabilization binder device.

d) For EMS units with long transport times and with patients requiring large volumes of fluid resuscitation, the patient will need to be periodically monitored to make sure that the device is not becoming too tight due to expansion of the pelvic area from accumulation of fluids that have third spaced to the pelvic area.

e) If providers feel the device is becoming too tight, it should be slowly loosened and then reapplied.
N4. On-Scene Protocol and Alternative Dispatch Protocol During Declared Public Health Emergency for Pandemic Influenza

This protocol is designed to be implemented only when there is a significant infectious disease that has impacted the health care system to the extent that all hospital beds are full, the EMS/Dispatch work force is significantly depleted due to absenteeism, and the calls for EMS support overwhelm resources to manage all calls. MIEMSS, in collaboration with DHMH and Local health officers, would activate this protocol to provide authorization for the adjustment in the prehospital standard of care.

MANAGING ARRESTS

If the patient is in cardiac arrest, CPR for 5 cycles, than apply AED. Shock and continue to shock with 5 cycles CPR if indicated.

1) If a pulse returns, initiate patient transport as quickly as possible to a higher level of medical care (the ED or rendezvous with ALS, whichever has a shorter ETA).

2) If no shock is indicated and there is no return of pulse, consult medical direction to withdraw care and leave patient on scene.

Follow normal Maryland Medical Protocol for EMS Providers and conduct General Patient Care assessment; make sure you are using appropriate universal precautions.

Follow the sequential steps below:

1) If patient has an obvious non-flu related illness or injury, apply appropriate Maryland Medical Protocol for EMS Providers, then treat and transport appropriately.

2) If patient has Critical Vital Signs (Table #1), transport patient to ED.

3) If patient has Normal Vital Signs (Table #1), then go to Case Definition Signs and Symptoms for Flu (Table #2).
   a) If the patient has three or more Case Definition Signs or Symptoms for Flu, transport patient to Alternate Care Facility.
   b) If the patient has two or less Case Definition Signs or Symptoms for Flu, EMS provider shall call for Medical Consult (state central resource physician) to determine if EMS provider can leave the patient on scene, and advise the patient to self-quarantine and call a nurse/public health hotline for further assistance.
<table>
<thead>
<tr>
<th>Table 1. Assess Patient’s Vital Signs</th>
<th>Critical Adult Vital Signs</th>
<th>Critical Pediatric Vital Signs</th>
<th>Normal Adult Vital Signs</th>
<th>Normal Pediatric Vital Signs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transport to ED</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulse/Perfusion</td>
<td>Equal or Greater than 130</td>
<td>CRT greater than 2 seconds</td>
<td>Less than 130</td>
<td>CRT less than or equal to 2 seconds</td>
</tr>
<tr>
<td>RR/Distress</td>
<td>Equal or Greater than 30</td>
<td>Greater than 45 or increased work of breathing Neonate: Less than 30 Infant: Less than 20 Child: Less than 15</td>
<td>Less than 30</td>
<td>Unlabored breathing or Neonate: 30–45 Infant: 20–45 Child: 15–45</td>
</tr>
<tr>
<td>Systolic BP</td>
<td>Less than 90</td>
<td>Neonates: Less than 60 Infants: Less than 70 Children under 10 years of age: Less than 70 + (2 x years)</td>
<td>Equal or Greater than 90</td>
<td>Neonates: Equal or greater than 60 Infants: Equal or greater than 70 Children under 10 years of age: Equal or greater than 70 + (2 x years)</td>
</tr>
<tr>
<td>Pulse Ox</td>
<td>Less than 92 on room air</td>
<td>Less than 92 on room air</td>
<td>Equal or Greater than 92</td>
<td>Equal or Greater than 92</td>
</tr>
<tr>
<td>AVPU</td>
<td>Pain or Unresponsive</td>
<td>Pain or Unresponsive</td>
<td>Alert or Verbal</td>
<td>Alert or Verbal</td>
</tr>
<tr>
<td>Lung sounds</td>
<td>Rales/Wheezing</td>
<td>Rales/Wheezing</td>
<td>Clear</td>
<td>Clear</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 2. Case Definition Signs and Symptoms for FLU</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Difficulty breathing with exertion</td>
</tr>
<tr>
<td>2. Has doctor-diagnosed flu</td>
</tr>
<tr>
<td>4. Fever</td>
</tr>
<tr>
<td>5. Shaking chills</td>
</tr>
<tr>
<td>6. Chest pain (pleuritic)</td>
</tr>
</tbody>
</table>
## Maximize the Use of Limited Resources Alternative Dispatch Protocols

<table>
<thead>
<tr>
<th>Dispatch Priority Level</th>
<th>Response (Standard Operating Mode)</th>
<th>Level 1(A) Activation of Card 36 and ONLY for use in 6, 10, 18, and 26 DSS1 BELOW IS BACK UP STRATEGY FOR EMD WITHOUT CARD 36</th>
<th>Level 2(B) Implement Declining Response / Configuration CAD Table (Moderate) + Card 36 (6,10,18 &amp; 26) DSS2</th>
<th>Level 3(C) Implement Declining Response / Configuration CAD Table (Severe) + Card 36 (6,10,18 &amp; 26) DSS 3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Classification 1 (‘Echo)</strong></td>
<td>Confirmed Cardiac Arrest (Not Breathing, Unresponsive per 911 call) (MPD cards - 2, 6, 9, 11,15, 31)</td>
<td>Closest AED Unit and Closest 1st Responder and Closest ALS Ambulance</td>
<td>Closest AED Unit and Closest 1st Responder and Closest BLS Ambulance if available</td>
<td>Closest AED Unit if available - If no unit available, no response</td>
</tr>
<tr>
<td><strong>Classification 2 (‘Delta)</strong></td>
<td>Life Threatening Emergency/Potentially Life Threatening/Confirmed Unstable Patient(s)</td>
<td>Closest 1st Responder and Closest ALS Ambulance</td>
<td>- Closest 1st Responder and Closest ALS Ambulance if available; - BLS ambulance if ALS unit not available</td>
<td>Closest 1st Responder and Closest Ambulance available (ALS or BLS)</td>
</tr>
<tr>
<td><strong>Classification 3 (‘Charlie)</strong></td>
<td>Non-Critical/Currently Stable Patient(s) Requiring ALS Assessment</td>
<td>Closest ALS Ambulance</td>
<td>Closest Ambulance available (ALS or BLS)</td>
<td>Closest Ambulance available (ALS or BLS)</td>
</tr>
<tr>
<td><strong>Classification 4 (‘Bravo)</strong></td>
<td>BLS Assessment for unknown/possibly dangerous scenes</td>
<td>Closest 1st Responder and Closest BLS Ambulance</td>
<td>Closest 1st Responder and Closest BLS Ambulance if available</td>
<td>Closest 1st Responder - Trauma Closest 1st Responder - Medical Referral to Nurse or Health Department Advice Phone service if available; or self-transport Alternate Care Site</td>
</tr>
<tr>
<td><strong>Classification 5 (‘Alpha)</strong></td>
<td>BLS Treatment</td>
<td>BLS Ambulance</td>
<td>Alternate Care Referral</td>
<td>Alternate Care Referral</td>
</tr>
<tr>
<td><strong>Classification 6 (‘Omega)</strong></td>
<td>Non-Ambulance Care</td>
<td>Alternate care such as Poison Control Center; Police/Fire service call, etc.</td>
<td>Alternate care such as Poison Control Center; Police/Fire service call, etc.</td>
<td>Alternate care such as Poison Control Center; Police/Fire service call, etc.</td>
</tr>
</tbody>
</table>
N5. AIRWAY MANAGEMENT: VIDEO LARYNGOSCOPY FOR OROTRACHEAL INTUBATION

1. PURPOSE
   Endotracheal Intubation using video laryngoscopy involves visualizing the glottic opening using specialized technology to view “around the corner” and pass the endotracheal tube, under optimal visualization, into the trachea. The purpose is to provide airway and ventilatory support for apnea, hypoxia, hypoventilatory respiratory failure, or respiratory insufficiency. The video laryngoscope device must have the following features:
   a) Color monitor
   b) Anti-fog mechanism
   c) Video recording device

2. INDICATION
   Video laryngoscopy and orotracheal intubation is indicated for patients who are 18 years or older.
   a) Apnea or agonal respirations
   b) Airway reflex compromised
   c) Ventilatory effort compromised
   d) Injury or illness involving the airway
   e) Potential for airway or ventilatory compromise

3. CONTRAINDICATIONS
   Patients less than 18 years of age.

4. POTENTIAL ADVERSE EFFECTS/COMPLICATIONS
   a) Trauma to the mouth, pharynx, larynx, trachea, esophagus
   b) Right mainstem bronchus intubation
   c) Vomiting
   d) Secondary brain injury resulting from hypoxia and/or hypotension
   e) Displacement of a properly placed endotracheal tube
   f) Esophageal intubation

5. PRECAUTIONS
   a) Attempt visualization and endotracheal intubation up to two times. If additional attempts are indicated, consult medical direction and consider what changes would result in improved visualization and success at endotracheal placement of the ET tube.
   b) Confirm placement of the endotracheal tube in the trachea as described in AIRWAY MANAGEMENT: OROTRACHEAL INTUBATION.
6. **PROCEDURE**  
   a) Insert the Video Laryngoscope Device midline into the pharynx.  
   b) Advance the Video Laryngoscope Device midline to center the vocal cords on the video screen.  
   c) Pass the endotracheal tube between the vocal cords, remove the stylet, and advance the tube to the desired depth.  
   d) Secure the endotracheal tube and verify correct placement.

7. **TRAINING AND DOCUMENTATION**  
   a) Providers must complete didactic and practical training.  
      (1) Description of technique  
      (2) Demonstration of device (features, operation, troubleshooting)  
      (3) Documentation requirements  
      (4) Mannequin scenarios  
      (5) In vivo practice  
   b) Providers must complete the Video Laryngoscopy Procedure Form after each patient encounter in which the Video Laryngoscope Device is used.  
   c) Program Medical Directors must review each patient encounter in which the Video Laryngoscope Device is used and provide a quarterly report to the Office of the Medical Director.
VIDEO LARYNGOSCOPY PROCEDURE FORM

PATIENT PROFILE
Age:_________ Gender:_________ Height:_________ Weight:_________

INDICATION
__ Apnea or agonal respirations
__ Airway reflex compromised
__ Ventilatory effort compromised
__ Injury or illness involving the airway
__ Potential for airway or ventilatory compromise

ASSESSMENT
Mouth Opening: ___ Thyromental Distance: ___ Adam’s Apple to Sternal Notch ___

PROCEDURE
Number of attempts: ______
Successful: ___ Yes ___ No
RSI procedure used? ___Yes ___ No

Confirmation of correct placement:
___ EtCO₂ waveform ___ Condensation in tube
___ Breath sounds present ___ Absence of epigastric sound
___ Chest rise ___ SpO₂
___ Other __________________________________________________________

For failed attempts: what prevented success?
___ Unable to visualize airway ___ Unable to place tube despite visualization
___ Technical issue ___ Dental injury
___ Bleeding/Secretions ___ Esophageal intubation
___ Other __________________________________________________________

Which device/procedure was used to rescue the failed airway?
___ EasyTube® ___ King LTS-D™
___ BVM Ventilation OPA/NPA ___ Cricothyroidotomy
N6. TRANSPORT TO SHORE EMERGENCY CENTER AT QUEENSTOWN FREESTANDING MEDICAL FACILITY (NEW ’15)

1. PURPOSE
The purpose of this protocol is to define the type of patient an EMS service may transport to a MIEMSS-designated freestanding medical facility.

2. INDICATIONS
A jurisdiction may allow transport of a patient meeting one or more of the following indications to a freestanding medical facility.
   a) A stable priority 2, 3, or 4 patient as outlined in The Maryland Medical Protocols for EMS Providers who does not need a time-critical intervention
   b) A priority 1 patient with an unsecured airway or in extremis that requires stabilization beyond the capability of the EMS crew (e.g., cardiac or respiratory arrest)

3. CONTRAINDICATIONS
Except as provided in #2, the following patients shall not be transported to a freestanding medical facility.
   a) Any patient meeting the criteria for transport to a trauma center or specialty referral center as defined in The Maryland Medical Protocols for EMS Providers
   b) A pregnant patient complaining of abdominal pain or a patient who is in active labor
   c) Any patient in need of time-critical intervention that can be provided only at a hospital-based Emergency Department

4. PROCEDURE
The EMS provider shall consult with the Queenstown freestanding medical facility (also designated as a Base Station) prior to arrival on all priority 1 and 2 transports as provided in #2 and, otherwise, when unclear of appropriate destination. The freestanding medical facility shall direct the provider to the appropriate destination.

5. SPECIAL CONSIDERATIONS
None
N7. ADULT SURGICAL CRICOTHYROIDOTOMY (NEW '15)

1. Initiate General Patient Care.

2. Presentation
   Patients must have reached their 15th birthday and may present with any of the following conditions:
   a) Inability to oxygenate despite having tried BVM with oropharyngeal/nasopharyngeal airway, ET placement, and supraglottic airway (if not contraindicated)
   b) Inability to place ET in the setting of life-threatening upper airway hemorrhage
   c) Completely obstructing upper airway foreign body that cannot be removed via BLS maneuvers or Magill forceps with direct visualization

3. Equipment:

   PROVIDERS MAY USE PRE-ASSEMBLED EQUIPMENT OR AN FDA-APPROVED KIT, AS PRESCRIBED BY THE PROGRAM MEDICAL DIRECTOR.

4. Procedure:
   a) Providers must use a designated technique and procedure for establishing the airway through the cricothyroid membrane that has been approved by the program medical director as part of this pilot.
   b) Upon completion of the skill (or at an appropriate time during the sequence of patient care) the provider will obtain medical direction and also notify the receiving physician/emergency department with the following information:
      • Patient condition
      • Reason for surgical cricothyroidotomy
      • Complications arising from procedure (if any)
      • Patient response to treatment

5. Surgical Cricothyroidotomy Quality Assurance Process
   a) Individual Paramedic Approval
      (1) Persons participating in this jurisdictional optional protocol will have completed all of the following:
         a. Classroom lecture
         b. Successful placement of device using pig trachea
         c. Substitute instruction and demonstration of skill proficiency may be approved by the program medical director on an individual basis.
b) Ongoing Demonstration of Proficiency
   (1) During biannual recertification classes, each paramedic will repeat the classroom lecture and placement of the device using the pig’s trachea.
   (2) Substitute instruction and demonstration of skill proficiency may be approved by the program medical director on an individual basis.

c) Review of Each Call
   (1) Documentation:
      a. The provider will thoroughly document the following on their Patient Care Report (PCR):
         i. Indications that led to performing cricothyroidotomy
         ii. Complications that arose from procedure
         iii. Patient response to treatment
   (2) Notifications:
      a. Immediate notification of EMS Supervisor following transfer of care to the receiving facility
      b. Notification of the EMSOP Quality Assurance Section within 24 hours of the event
      c. Notification of the program medical director within 24 hours of the event
   (3) Individual Event Review
      a. Each use of this Jurisdictional PILOT Protocol will be reviewed by the EMSOP for correct application and technique.
   (4) The EMSOP will maintain a detailed surgical cricothyroidotomy procedure database and will provide an annual report to the State EMS Medical Director.
MOBILE INTEGRATED COMMUNITY HEALTH PILOT PROGRAM (NEW '15)

1. PURPOSE
The purpose of this pilot protocol is to establish guidelines for the Mobile Integrated Community Health Pilot Program (MICHPP). The MICHPP is part of a jurisdictional or regional "wellness committee" that will be called the Shore Wellness Committee for this pilot program. The Shore Wellness Committee has, at a minimum, representatives from a Jurisdictional EMS Operational Program (EMS Medical Director and EMS Operations), local health department, and local/ regional hospital system(s). This program is established to identify individuals who frequently utilize 9-1-1 for non–life-threatening or medical reasons and to assist in linking them with community resources and unexplored medical/social programs that will most appropriately meet their needs. The MICHPP uniformed paramedic may perform an abuse/neglect evaluation, conduct a home safety check, perform vital sign acquisition (i.e., temperature, pulse, RR, BP, pulse oximetry) for the nurse practitioner/registered nurse (NP/RN) and document findings jointly with the NP/RN. The NP/RN will perform the individual assessment, medication reconciliation/compliance, make referrals, interface with the primary health care professional/physician, and make recommendations to the patient.

2. INDICATIONS
Individuals who will qualify for a home visit by the MICHPP team (consisting of a nurse practitioner/registered nurse and experienced paramedic) include:
   a) Individuals who have called 9-1-1 for any medically-related reason five times in any six-month interval. Individuals may be referred to the MICHPP by other allied health professionals with the individual’s consent.
   b) Patient must be 18 years of age or older.

3. PRECAUTIONS
Upon initiation of the home visit, if any individual were to exhibit any signs or symptoms that would require transport to an Emergency Department, the MICHPP team will contact the county dispatch center who will be directed to generate an emergent response for that individual.
   a) The Mobile Integrated Community Health Pilot Program paramedic will perform all assessments and care based on current Maryland Medical Protocols for EMS Providers until the appropriate EMS resource’s arrival; care may then be transferred to that EMS unit. The NP/RN cannot direct the paramedic to perform any skill or medical intervention that is not within his or her scope of practice nor provide “Medical Consultation” as referenced in The Maryland Medical Protocols for EMS Providers.
4. CONTRAINDICATIONS
Individuals who will not qualify for this program include:

a) Individuals already receiving care from a patient-centered medical home (PCMH) or who have already established individual home health care or use a visiting nurse agency
b) Individuals who refuse participation by revoking written consent, verbal refusal of care at time of visit, or integration into programs as in 4.a above

5. PROCEDURE
a) After an individual has consented to be included in this program, a scheduled home visit will be performed as follows:
   (1) Uniformed paramedic will:
      a. Provide a recognized uniformed presence for individual reassurance and familiarity.
      b. Assess the individual’s home.
         a. Assess for signs of neglect or abuse.
         b. Assess for safety issues (e.g., slip/fall risk, smoke detector, fire, exposed electrical).
      c. Obtain basic vital signs.
         a. Heart rate
         b. Blood pressure
         c. Pulse oximetry
         d. Respiratory quality and rate
         e. Temperature
         f. Weight

   PARAMEDIC WILL NOT BE PERFORMING BLOOD DRAWS, MEDICATION ADMINISTRATION, OR ALS INTERVENTIONS UNLESS AN IMMEDIATE LIFE-THREATENING CONDITION HAS BEEN IDENTIFIED AND THE 9-1-1 CENTER HAS BEEN NOTIFIED AND AN EMS RESPONSE INITIATED.

   (2) NP/RN will
      a. Evaluate for any immediate life-threatening condition.
      b. Assess for signs of neglect or abuse.
      c. Review vital signs.
      d. Obtain and review the individual’s past medical history.
      e. Determine the individual’s family and social history.
      f. Review medication.
      g. Review behavioral health.
      h. Conduct a basic physical assessment including a focused review of systems.
      i. Make appropriate health professional contacts, medication modifications, education, and referrals.
6. MEDICAL CONSULTATION as defined in *The Maryland Medical Protocols for EMS Providers*
   a) Obtained through Jurisdictional EMS Medical Director or designated Base Station
   b) Paramedics cannot accept orders from primary care physicians on the phone or on-scene unless individual has an immediate life-threatening condition and the physician is going to the hospital with individual on EMS unit.

7. DOCUMENTATION AND DATA COLLECTION
   a) All data (by paramedic/NP/RN) will be collected through “All Scripts” using data points similar to established Shore Wellness program.
   b) In the event that an immediate life-threatening condition is identified and the MICHPP paramedic initiated EMS care
      (1) The MICHPP paramedic shall complete an entire eMEDS® report documenting care provided.
      (2) The NP/RN will complete the “All Scripts” report documenting the activation of an EMS response due to immediate life-threatening condition and NP/RN individual care provided.

8. QUALITY ASSURANCE/QUALITY IMPROVEMENT
   a) All calls will be reviewed by a Shore Wellness QA Committee consisting of Nursing, EMS, Administrative, and EMS Medical Director.
   b) Quarterly data reports will be generated to the Office of the State EMS Medical Director and to the Shore Wellness Committee.